logo-loader
RNS
GenIP PLC

US$200,000 Convertible Loan Note with Tekcapital

RNS Number : 2928B
GenIP PLC
02 November 2026
 


 

 

GenIP Plc

("GenIP" or the "Company")

 

US$200,000 Convertible Loan Note Facility with Tekcapital Europe Ltd

 

GenIP Plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, announces that it has entered into a US$200,000 Convertible Loan Note Instrument (the "Loan Notes") with Tekcapital Europe Ltd ("Tekcapital Europe"), a wholly owned subsidiary of Tekcapital plc. 

 

The Board believes this investment, representing approximately 23 per cent of GenIP's current market capitalisation, reflects Tekcapital's continued confidence in the Company's strategy, technology and long-term growth prospects. 

 

The proceeds of the Loan Notes will be used to support the commercial rollout of the Company's new subscription-based SaaS platform for technology transfer decision-making and to further advance the Company's growth strategy as it seeks to expand adoption of its technology and services across the innovation ecosystem. 

 

The Loan Notes have a term of four years from the date of issue and carry interest at a rate of 10 per cent per annum, accruing and compounding over the life of the instrument. Both principal and accrued interest may be converted into new ordinary shares in the Company. 

 

The conversion price shall be equal to the closing mid-market price of the Company's ordinary shares on the trading day immediately preceding the date of conversion. 

 

As the conversion price will be determined by reference to the prevailing market price at the time of conversion, the number of ordinary shares which may ultimately be issued upon conversion cannot be determined at the date of this announcement. The Company will make further announcements as and when any conversion occurs. 

 

The Company may redeem the Loan Notes, together with accrued interest, at any time prior to maturity without penalty. The Loan Notes are unsecured. 

 

Rule 9 Considerations 

The Tekcapital concert party currently holds approximately 48.95 per cent. of the Company's voting rights and any conversion of the Loan Notes is therefore subject to the restrictions contained in Rule 9 of the City Code on Takeovers and Mergers. 

 

Accordingly, any conversion of the Loan Notes or accrued interest may only take place to the extent that such conversion would not cause Tekcapital to make a mandatory offer for the Company under Rule 9 of the Takeover Code. 

The conversion rights attaching to the Loan Notes are therefore subject to compliance with the requirements of the Takeover Code. 

 

Related Party Transaction 

As Tekcapital Europe is a wholly owned subsidiary of Tekcapital plc, a substantial shareholder of the Company, the Loan Notes constitute a related party transaction pursuant to AIM Rule 13 of the AIM Rules for Companies. 

 

Accordingly, the Directors of the Company, with the exception of Lord David Willetts who is involved in the transaction by reason of being a non-executive director of Tekcapital plc, having consulted with the Company's Nominated Adviser, consider the terms of the Loan Notes to be fair and reasonable insofar as the Company's shareholders are concerned. 

 

Melissa Cruz, Chief Executive Officer of GenIP, commented: "This financing represents a significant commitment to GenIP and provides further validation of the strategy we are executing. As we enter the commercial rollout phase of our new subscription-based SaaS platform, the Facility provides additional flexibility to accelerate growth initiatives and expand our market presence. 

 

“The support from Tekcapital is particularly meaningful given the scale of the investment relative to the Company's current valuation and demonstrates confidence in both the progress achieved to date and the opportunities ahead. We believe GenIP is entering an exciting phase of development, and this investment strengthens our position as we continue to execute our strategy and create long-term value for shareholders." 

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc

Melissa Cruz, CEO

 

Via Walbrook PR

 

 

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

Tel: +44 (0) 20 7628 3396

 

 

AlbR Capital Limited (Joint Broker)

Colin Rowbury

Jon Belliss

Tel: +44 (0) 20 7399 9427

cr@albrcapital.com 

Jb@albrcapital.com

 

 

CMC Markets (Joint Broker)

Douglas Crippen

Tel: + 44 (0) 203 003 8632

 

 

 

Walbrook PR (Financial PR)

Alice Woodings

William Turner

GenIP@walbrookpr.com

Tel: +44 (0) 7407 804 654

Tel: +44 (0) 7407 020 470

 

 

focusIR (Investor Relations)

Kat Perez

Dr Paul Cornelius

GenIP@focusIR.com

Tel: +44 (0) 20 4570 2234

Tel: +44 (0) 20 4570 2246

 

 

 

About GenIP

GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

 

Service Offerings

GenIP operates through two synergistic service lines:

 

Service

Description

Value Proposition

Invention Intelligence Product Suite

AI-powered market intelligence reports assessing the commercial potential of emerging technologies

Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy

 

IP Commercialisation Services

 

 

End-to-end engagement to help research organisations commercialise innovations

 

 

Provides cost-effective, broad support to achieve our clients' strategic objectives

 

 

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

 

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

 

  • Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

  • Service Deepening
    Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
  • Strategic Acquisitions
    Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODEAKFFESAKFFA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read